Seven Physicians in Amarillo, TX Contract with GenoMed to Distribute the Company's Treatments to Their 21,000 Patients
Thursday May 6, 12:05 pm ET
ST. LOUIS, May 6 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, announced today that Dr. John Young, a leader in his medical community of Amarillo, TX, has convinced seven family physician colleagues to distribute GenoMed's protocols to their patients. Together, they care for over 21,000 patients.
ADVERTISEMENT
Said Dr. David Moskowitz, GenoMed's Chief Medical Officer and CEO, "I am delighted by Dr. Young's effectiveness in educating his medical community about the superior patient outcomes which GenoMed can deliver to patients with hypertension, diabetes, and emphysema. I look forward to working with these outstanding general practitioners, and salute their courage in embracing the latest in medical genomics to help their patients."
About GenoMed
GenoMed is leading the medical revolution which medical genomics has already made possible. The Company's business model is as novel as its science. GenoMed's Clinical Outcomes Improvement Program(TM) is available to any patient for the nominal subscription fee of $67 a month ($800 per year). Physicians who participate in GenoMed's Clinical Outcomes Improvement Network(TM) have the satisfaction of delivering cutting-edge medicine while enhancing their clinical revenue. GenoMed is currently marketing its protocol for delaying complications of high blood pressure and diabetes including kidney failure. Hypertension and diabetes affect 80 million Americans, are responsible for two-thirds of deaths in the U.S., and account for a similar proportion of healthcare costs. GenoMed intends to demonstrate cost-savings by keeping patients healthier.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether these seven physicians are able to recruit any of their patients to subscribe to GenoMed's Clinical Outcomes Improvement Program(TM); (b) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
biz.yahoo.com
--------------------------------------------------------------------------------
Source: GenoMed, Inc. |
